{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:08:16Z","timestamp":1772759296456,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.3816\/cbc.2007.n.009","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:05:01Z","timestamp":1221080701000},"page":"543-549","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Efficacy and Safety of Ixabepilone, a Novel Epothilone Analogue"],"prefix":"10.3816","volume":"7","author":[{"given":"Xavier","family":"Pivot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armelle","family":"Dufresne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Villanueva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CBC.2007.n.009_bib1","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1053\/j.seminoncol.2005.09.013","article-title":"Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR)","volume":"32","author":"Lee","year":"2005","journal-title":"Semin Oncol"},{"key":"10.3816\/CBC.2007.n.009_bib2","first-page":"21","article-title":"The Pat-21 breast cancer model derived from a patient with primary Taxol\u00ae resistance recapitulates the phenotype of its origin, has altered \u03b2-tubulin expression and is sensitive to ixabepilone","volume":"47","author":"Jordan","year":"2006","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.3816\/CBC.2007.n.009_bib3","first-page":"1429","article-title":"BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy","volume":"7","author":"Lee","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CBC.2007.n.009_bib4","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1021\/bi0121611","article-title":"Epothilone and paclitaxel: unexpected differences in promoting the assembly and stabilisation of yeast microtubules","volume":"41","author":"Bode","year":"2002","journal-title":"Biochemistry"},{"key":"10.3816\/CBC.2007.n.009_bib5","first-page":"1195","article-title":"Taxane-based reversal agents modulate drug resistance mediated by P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein","volume":"2","author":"Brooks","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.3816\/CBC.2007.n.009_bib6","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1200\/JCO.2006.08.7304","article-title":"Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas","volume":"25","author":"Aghajanian","year":"2007","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CBC.2007.n.009_bib7","first-page":"89s","article-title":"Ixabepilone given weekly in patients with advanced malignancies: final efficacy and safety results of a phase I trial","volume":"24","author":"Dickson","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CBC.2007.n.009_bib8","first-page":"40s","article-title":"Phase II clinical trial of ixabepilone in metastatic breast cancer (MBC) patients previously untreated with taxanes","volume":"24","author":"Denduluri","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CBC.2007.n.009_bib9","first-page":"568s","article-title":"Phase II study of ixabepilone in patients (pts) with taxane-resistant metastatic breast cancer (MBC): final report","volume":"24","author":"Conte","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CBC.2007.n.009_bib10","first-page":"42s","article-title":"Phase II trial of ixabepilone in patients with metastatic breast cancer (MBC) who are resistant to an anthracycline, a taxane and capecitabine","volume":"24","author":"Thomas","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2007.n.009_bib11","unstructured":"Pivot X, Thomas E, Lerzo G. Ixabepilone in patients with metastatic breast cancer who are resistant to an anthracycline, a taxane and capecitabine. Presented at: 31st European Society of Medical Oncology Congress; September 29-October 3, 2006; Istanbul, Turkey."},{"issue":"16 suppl","key":"10.3816\/CBC.2007.n.009_bib12","first-page":"25s","article-title":"Phase II genomics study in patients receiving ixabepilone as neoadjuvant treatment for breastcancer (BC): preliminary efficacy and safety data","volume":"23","author":"Llombart Cussac","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2007.n.009_bib13","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1054\/bjoc.1999.0958","article-title":"A unified definition of clinical anthracycline resistance breast cancer","volume":"82","author":"Pivot","year":"2000","journal-title":"Br J Cancer"},{"issue":"18 suppl","key":"10.3816\/CBC.2007.n.009_bib14","first-page":"568s","article-title":"Final efficacy results of a phase I\/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline","volume":"24","author":"Bunnell","year":"2006","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CBC.2007.n.009_bib15","first-page":"648s","article-title":"A phase II study of ixabepilone (BMS 247550) in metastatic renal cell carcinoma","volume":"24","author":"Posadas","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2007.n.009_bib16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1200\/jco.2004.22.90140.4012","article-title":"A phase II trial of epothilone B analogue BMS-247550 (NSC #710428) in patients with advanced pancreas cancer: a Southwest Oncology Group study","volume":"22","author":"Whitehead","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2007.n.009_bib17","first-page":"626","article-title":"A randomized phase II study of epothilone analog BMS-247550 in patients (pts) with nonsmall cell lung cancer (NSCLC) who have failed first-line platinumbased chemotherapy","volume":"22","author":"Vansteenkiste","year":"2003","journal-title":"J Clin Oncol"},{"issue":"18 suppl","key":"10.3816\/CBC.2007.n.009_bib18","first-page":"231s","article-title":"Clinical outcome of taxane-resistant (TR) hormone refractory prostate cancer (HRPC) patients (pts) treated with subsequent chemotherapy (ixabepilone (Ix) or mitoxantrone\/prednisone (MP)","volume":"24","author":"Lin","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2007.n.009_bib19","doi-asserted-by":"crossref","first-page":"8724","DOI":"10.1200\/JCO.2005.02.4448","article-title":"Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111","volume":"23","author":"Hussain","year":"2005","journal-title":"J Clin Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911707443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911707443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:10:34Z","timestamp":1761513034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820911707443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S1526820911707443"],"URL":"https:\/\/doi.org\/10.3816\/cbc.2007.n.009","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Ixabepilone, a Novel Epothilone Analogue","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CBC.2007.n.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}